Navigation Links
Data Presented at DDW About Rebound Symptoms in Healed Erosive Esophagitis Patients After Completion of Treatment with DEXILANT(TM) (dexlansoprazole)
Date:5/5/2010

eating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD) for four weeks.

Important Safety Information

DEXILANT is contraindicated in patients with known hypersensitivity to any component of the formulation. Hypersensitivity and anaphylaxis have been reported with DEXILANT use. Symptomatic response with DEXILANT does not preclude the presence of gastric malignancy.

The most commonly reported treatment-emergent adverse reactions include diarrhea (4.8%), abdominal pain (4.0%), nausea (2.9%), upper respiratory tract infection (1.9%), vomiting (1.6%), and flatulence (1.6%). DEXILANT must not be co-administered with atazanavir because atazanavir systemic concentrations may be substantially decreased.

DEXILANT may interfere with the absorption of drugs for which gastric pH is important for bioavailability (e.g., ampicillin esters, digoxin, iron salts, ketoconazole). Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Concomitant tacrolimus use may increase tacrolimus whole blood concentrations.

Please click here for full prescribing information and visit the DEXILANT Web site at w
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data From LigoCytes Clinical Studies of Norovirus VLP Vaccine Presented at 13th Annual Conference on Vaccine Research
2. 12 Month Follow-Up Data for Isotope-Free Breast IORT Presented at ASBS Meeting
3. iFuse Implant System(TM) to be Presented at Leading Minimally Invasive Spine Surgical Meetings
4. Kristalose(R) Clinical Data to Be Presented at Digestive Disease Week(R) Meeting
5. Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent
6. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
7. New PLATO Sub-Analysis of CABG Patients Presented at ACC
8. Key Caldolor(R) Orthopedic Data to Be Presented at American Academy of Orthopaedic Surgeons Annual Meeting
9. STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting
10. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
11. Data From Three Clinical Studies of bioTheranostics Breast Cancer Molecular Test Presented at CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Rigrodsky & Long, P.A.: , Do ... LCI )? , Did you purchase your shares ... 16, 2014, inclusive? , Did you lose money in ... want to discuss your rights? Rigrodsky ... Timothy J. MacFall , announces that a complaint has been ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com announces that ... its catalogue: Germany Aesthetic Lasers and ... http://www.reportlinker.com/p02343442/Germany-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Germany Aesthetic ... Summary GlobalData,s new report, "Germany Aesthetic ... provides key market data on the Germany Aesthetic ...
(Date:8/28/2014)... Pharmatech initiated enrollment for its AccessPPM ... method for matching cancer patients to cancer clinical ... specific cancers, disease staging, and genetic mutations - ... in the first place. The challenge that the ... be well known to the patient or even ...
Breaking Medicine Technology:Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Germany Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2
... time you consider popping a,pill when you have trouble ... senior psychiatrist at the Scripps Clinic Sleep Center in ... regularly can,increase the risk of skin cancer., Daniel ... studies,involving sleeping pills and cancer, has just been published ...
... Research Relationships and Proven, Track Record ... SANTA CLARA, Calif., Aug. 18 NewCardio, Inc.,(OTC ... company, today,announced that Vincent W. Renz has joined ... Company,s commercialization effort, to include,business development, client services, ...
Cached Medicine Technology:Prescription Sleeping Pill Use Tied to Cancer 2Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4
(Date:8/28/2014)... American adults who are beginning to ... will now have a simpler way to connect with ... this year, some of the best life insurance rates ... , The promoted plans that included price data revealed ... popular policies. The term, guaranteed and modified plans that ...
(Date:8/28/2014)... York (PRWEB) August 28, 2014 ... bellwether trial of a transvaginal mesh lawsuit ( ... Inc., Bernstein Liebhard LLP reports. Court documents pending ... West Virginia indicate that the case was filed ... undergo two revision surgeries, allegedly due to vaginal ...
(Date:8/28/2014)... Vernon, Ind. (PRWEB) August 28, 2014 ... of Valero Energy Corporation (NYSE: VLO), and the Ports ... state and local officials today at a Port Appreciation ... purchased Mount Vernon ethanol plant. , “The opening of ... Vernon is another economic development win for the ...
(Date:8/28/2014)... take wing? Did they fall from trees and learn to ... along the ground and pump their "arms" to get aloft? ... past, but a new University of California, Berkeley, study provides ... ability to maneuver in midair, a talent that could have ... a perch. , The study looked at how baby birds, ...
(Date:8/28/2014)... of Medicine published research results on Aug. 21 ... safely reduce the viral load and clinical illness of ... (RSV). , Le Bonheur Children,s Hospital and ... Disease Specialist John DeVincenzo, MD, is lead author of ... common cause of lower respiratory tract infections in young ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Flapping baby birds give clues to origin of flight 2Health News:Flapping baby birds give clues to origin of flight 3Health News:DeVincenzo study breakthrough in RSV research 2
... will save lives this holiday season, NEW ... Friday" and the holiday season, New York Blood ... the children and,families whose lives are stricken by ... survival. Among these diseases are: Leukemia,and other forms ...
... efforts through second Innovation Event, INDIANAPOLIS, ... WLP ), the,nation,s largest health insurance company ... will begin accepting applications for its second ... innovation,partnership efforts by providing an accelerated process ...
... lead to vaccine that works , , THURSDAY, Nov. 13 (HealthDay ... has failed, but researchers report that they,ve still gained insight ... "It,s raised a whole new set of questions that are ... to a successful vaccine," said Dr. Susan P. Buchbinder, lead ...
... ... hospitals, ... announced HealthBIT, a healthcare business intelligence platform for,hospitals. HealthBIT(TM) provides ... and comparing their,data to provide actionable opportunities that result in ...
... shows economic,stress takes toll on the emotional and ... conducted by the American Psychological Association, shows,at least ... economy as their top,stressors. More than half, reported ... anger. Forty-six percent indicated they,were worried about providing ...
... options dwindle or are exhausted, terminally ill-patients often ... therapies. However, a team of researchers from Wake ... Medical Center and Unity Health System, report that ... governing end-of-life care may be leaving many medical ...
Cached Medicine News:Health News:A Thanksgiving Message From New York Blood Center 2Health News:A Thanksgiving Message From New York Blood Center 3Health News:WellPoint Announces Second Annual Innovation Event 2Health News:WellPoint Announces Second Annual Innovation Event 3Health News:HIV Vaccine Failure Still Brings Insights 2Health News:Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform 2Health News:Economic Stress Takes Toll on Health 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 2Health News:Doctors' questions about end-of-life legalities may result in patient pain 3
For the quantitative in vitro determination of CK-MB in serum and plasma...
The ALT method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alanine aminotransferase activity in serum or plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... S-1™ Biodegradable Anteroir Cervical System, in conjunction ... with a collar), is intended for use ... fusion procedures as a means to maintain ... or autografts., This device is not intended ...
Medicine Products: